96% Britons develop antibodies after one dose of COVID-19 vaccine

NEW DELHI: A report published in The Guardian states that a research found that over 90 per cent of Britons developed antibodies against coronavirus after one dose of COVID-19 vaccine (AstraZeneca or Pfizer). It added that almost 100 per cent develop it after the second dose of COVID-19 vaccine.

Researchers from the University College London (UCL) found that both the vaccines were equally efficient in triggering antibodies against the virus. Dr Maddie Shrotri, Lead Author, said that this is one of the earliest real-world vaccine studies in the United Kingdom (UK). Almost 9 out of 10 adults in the UK who were administered with either Pfizer or AstraZeneca vaccine produced antibodies against the novel coronavirus within a month of the first dose.

The findings were analysed on the basis of 13,232 antibody samples provided by 8,517 adults from England and Wales in the trial. The participants did not have antibodies before they had their first dose of vaccine. The UCL Virus Watch project team found that the vaccines stimulated the production of fewer antibodies in older people than the younger ones. However, after the second dose the antibodies were uniformly produced in people of all ages.

Professor Rob Aldridge, Chief Investigator, UCL Virus Watch, said that data shows that for older adults and for people with pre-medical conditions, the antibody response is a little weaker after the first dose of vaccine but was strong after the second dose. He added that this is the reminder of getting the second dose of vaccine and also that the vaccines are our only way out of the pandemic.